Program
icatibant
Also written as “Icatibant”, “Icatibant Injection (Icanticure®)” and “TAK-667”.
Its studies are mostly in Angioedemas, Hereditary · Angioedema · Osteoarthritis, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 90 open or running | phase 3since Nov 26, 2004 | Nov 26, 2004 | none ahead |
| Nang Kuang Pharmaceutical | 10 open or running | phase 4since Mar 12, 2025 | Mar 12, 2025 | none ahead |
| Sanofi | 10 open or running | phase 2since Mar 14, 2006 | Mar 14, 2006 | none ahead |
Also a collaborator on its studies: jerini-ag and ppd-development-lp.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 26, 2004First study: phase 3 study in AngioedemaNew to TakedaTakeda · NCT00097695 · 84 enrolled · United States
- Mar 14, 2006Sanofi's first study: phase 2 study in Joint DiseasesNew to SanofiSanofi · NCT00303056 · 590 enrolled · United States, Austria, Czech Republic and more
- Jul 12, 2007Phase 3 study in Angioedemas, HereditaryTakeda · NCT00500656 · 85 enrolled · Italy
- Jun 2, 2009Phase 3 study in Angioedemas, HereditaryTakeda · NCT00912093 · 98 enrolled · United States, Australia, Canada and more
- Oct 16, 2009Phase 3 study in Angioedemas, HereditaryTakeda · NCT00997204 · 151 enrolled · Argentina, Austria, Denmark and more
- Jun 28, 2011Phase 3 study in Angioedemas, HereditaryTakeda · NCT01386658 · 32 enrolled · United States, Australia, Austria and more
- Jul 25, 2013Phase 3 study in Angiotensin Converting Enzyme Inhibitor Induced AngioedemaTakeda · NCT01919801 · 118 enrolled · United States, Canada, Israel and more
- Jan 13, 2014Phase 1 study in Angioedemas, HereditaryTakeda · NCT02045264 · 12 enrolled · United States
- Mar 20, 2019Phase 3 study in Angioedemas, HereditaryTakeda · NCT03888755 · 8 enrolled · Japan
- Nov 29, 2020Phase 3 study in Angioedemas, HereditaryTakeda · NCT04654351 · 2 enrolled · Japan
- Mar 12, 2025Nang Kuang Pharmaceutical's first study: phase 4 study in Angioedemas, HereditaryNew to Nang Kuang PharmaceuticalNang Kuang Pharmaceutical · NCT07290855 · 5 enrolled · Taiwan
TargetBeta
“Bradykinin B2 receptor antagonist”ChEMBL 37, by rule
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07290855Angioedemas, Hereditary · Taiwan | 4 | Completed | Nang Kuang Pharmaceutical | May 27, 2025 | 5 |
| NCT04654351Angioedemas, Hereditary · Japan | 3 | Completed | Takeda | Jul 27, 2021 | 2 |
| NCT03888755Angioedemas, Hereditary · Japan | 3 | Completed | Takeda | Feb 12, 2016 | 8 |
| NCT02045264Angioedemas, Hereditary · United States | 1 | Completed | Takeda | Feb 27, 2014 | 12 |
| NCT01919801Angiotensin Converting Enzyme Inhibitor Induced Angioedema · United States, Canada, Israel and more | 3 | Completed | Takeda | Aug 22, 2015 | 118 |
| NCT01386658Angioedemas, Hereditary · United States, Australia, Austria and more | 3 | Completed | Takeda | Mar 12, 2018 | 32 |
| NCT00997204Angioedemas, Hereditary · Argentina, Austria, Denmark and more | 3 | Completed | Takeda | Jun 22, 2011 | 151 |
| NCT00912093Angioedemas, Hereditary · United States, Australia, Canada and more | 3 | Completed | Takeda | Oct 1, 2010 | 98 |
| NCT00500656Angioedemas, Hereditary · Italy | 3 | Completed | Takeda | Jul 25, 2006 | 85 |
| NCT00303056Joint Diseases · United States, Austria, Czech Republic and more | 2 | Completed | Sanofi | Jul 2007 | 590 |
| NCT00097695Angioedema · United States | 3 | Completed | Takeda | Jul 17, 2006 | 84 |
How it is read
Names in the registry
- “Icatibant”, 6 entries
- “Icatibant Injection (Icanticure®)”, 1 entry
- “TAK-667”, 1 entry
- “icatibant”, 1 entry
- “Icatibant (30 mg)”, 1 entry
Conditions, from the studies’ own filings
- Angioedemas, Hereditary, 9 studies
- Angioedema, 1 study
- Osteoarthritis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.